Headlines about CTD (OTCMKTS:CTDH) have trended somewhat positive this week, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CTD earned a daily sentiment score of 1.14 on their scale. InfoTrie also assigned media coverage about the biotechnology company an news buzz score of 10 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock’s share price in the next several days.

CTD stock opened at $0.80 on Friday. CTD has a 1-year low of $0.25 and a 1-year high of $0.95.

TRADEMARK VIOLATION WARNING: “CTD (CTDH) Given Daily News Impact Rating of 1.14” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2018/11/10/ctd-ctdh-given-daily-news-impact-rating-of-1-14.html.

About CTD

CTD Holdings, Inc, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. The company's lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Neimann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs.

See Also: Buyback

Receive News & Ratings for CTD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTD and related companies with MarketBeat.com's FREE daily email newsletter.